保乳术的现状及存在的问题

doi:10.3760/cma.j.issn.1673-422X.2017.07.019

摘要/Abstract

摘要： 保乳手术联合放疗与乳腺癌根治手术在预后上无差别，但保乳术相对于根治术具有创伤小、出血少、感染率低等优点，使患者的生命质量得到提高。在实践过程中，由于受到病情、患者、医师、社会经济、临床、安全性等多方面的影响，保乳术在医患沟通、社会经济、外观美学、切缘、影像评估、临床精细操作等方面仍存在许多争议。同时，新的外科技术如整形保乳术以及新的术中评估设备如MarginProbe边缘评估系统等新发展也带来了新的思路。

关键词: 乳腺肿瘤, 乳房切除术, 区段

Abstract: There is no difference between breast conserving surgery (BCS) combined with radiotherapy and radical surgery in outcomes. However, comparing with the radical surgery, BCS has little trauma, less bleeding and lower infection rate, which makes patients′ quality of life improved. In the practice of BCS, due to the disease, patients, physicians, socioeconomic, clinical, security and many other factors, there are still many controversial issuesin the doctorpatient communication, socioeconomic, aesthetic, margins width, precision operation procedures of BCS. At the same time, new surgical techniques such as plastic breast conserving surgery, and new intraoperative assessment equipment such as MarginProbe system and other new technology development has brought us new ideas to solve these problems.

Key words: Breast neoplasms, Mastectomy, segmental

蔡汶润，杨正军，曹旭晨. 保乳术的现状及存在的问题[J]. 国际肿瘤学杂志, 2017, 44(7): 550-553.

Cai Wenrun, Yang Zhengjun, Cao Xuchen. Current situation and problems of breast conserving surgery[J]. Journal of International Oncology, 2017, 44(7): 550-553.

参考文献

［1］ Katz SJ, Lantz PM, Janz NK, et al. Patient involvement in surgery treatment decisions for breast cancer［J］. J Clin Oncol, 2005, 23(24): 5526-5533. DOI: 10.1200/JCO.2005.06.217. ［2］ Zhang L, Jiang M, Zhou Y, et al. Survey on breast cancer patients in China toward breastconserving surgery［J］. Psychooncology, 2012, 21(5): 488-495. DOI: 10.1002/pon.1922. ［3］ Fan L, StrasserWeippl K, Li JJ, et al. Breast cancer in China［J］. Lancet Oncol, 2014, 15(7): e279-e289. DOI: 10.1016/S1470-2045(13)70567-9 . ［4］ Nguyen BC, Alawadi ZM, Roife D, et al. Do socioeconomic factors and race determine the likelihood of breastconserving surgery?［J］. Clin Breast Cancer, 2016, 16(4): e93-e97. DOI: 10.1016/j.clbc.2016.05.008. ［5］ Schwartz GF, Veronesi U, Clough KB, et al. Proceedings of the consensus conference on breast conservation, April 28 to May 1, 2005, Milan, Italy［J］. Cancer, 2006, 107(2): 242250. DOI: 10.1002/cncr.21988. ［6］ Litière S, Werutsky G, Fentiman IS, et al. Breast conserving therapy versus mastectomy for stage ⅠⅡ breast cancer: 20 year followup of the EORTC 10801 phase 3 randomised trial［J］. Lancet Oncology, 2012, 13(4): 412-419. DOI: 10.1016/S1470-2045(12)70042-6. ［7］ Shin HC, Han W, Moon HG, et al. Limited value and utility of breast MRI in patients undergoing breastconserving cancer surgery［J］. Ann SurgOncol, 2012, 19(8): 2572-2579. DOI: 10.1245/s10434-012-2289-3. ［8］ Houssami N, Ciatto S, Macaskill P, et al. Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and metaanalysis in detection of multifocal and multicentric cancer［J］. J ClinOncol, 2008, 26(19): 3248-3258. DOI: 10.1200/JCO.2007.15.2108. ［9］ Turnbull L, Brown S, Harvey I, et al. Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial［J］. Lancet, 2010, 375(9714): 563-571. ［10］ Arvold ND, Taghian AG, Niemierko A, et al. Age, breast cancer subtype approximation, and local recurrence after breastconserving therapy［J］. J ClinOncol, 2011, 29(29): 3885-3891. DOI: 10.1200/JCO.2011.36.1105. ［11］ Azim HA, Partridge AH. Biology of breast cancer in young women［J］. Breast Cancer Res, 2014, 16(4): 427. DOI: 10.1186/s13058-014-0427-5. ［12］ Rosenberger LH, Mamtani A, Fuzesi S, et al. Early adoption of the SSOASTRO consensus guidelines on margins for breastconserving surgery with wholebreast irradiation in stage Ⅰ and Ⅱ invasive breast cancer: initial experience from memorial sloankettering cancer center［J］. Ann SurgOncol, 2016, 23(10): 3239-3246. DOI: 10.1245/s10434-016-5397-7. ［13］ Esposito A, Criscitiello C, Curigliano G. Highlights from the 14(th) St Gallen International Breast Cancer Conference 2015 in Vienna: dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer［J］. Ecancermedicalscience, 2015, 9: 518. DOI: 10.3332/ecancer.2015.518. ［14］ Merrill AL, Tang R, Plichta JK, et al. Should new "no ink on tumor" lumpectomy margin guidelines be applied to ductal carcinoma in situ (DCIS)? A retrospective review using shaved cavity margins［J］. Ann SurgOncol, 2016, 23(11): 3453-3458. DOI: 10.1245/s10434-016-5251-y. ［15］ Morrow M, Van Zee KJ. Margins in DCIS: does residual disease provide an answer?［J］. Ann SurgOncol, 2016, 23(11): 3423-3425. DOI: 10.1245/s10434-016-5255-7. ［16］ Wang S, Zhang Y, Yang X, et al. Shrink pattern of breast cancer after neoadjuvant chemotherapy and its correlation with clinical pathological factors［J］. World J SurgOncol, 2013, 11(1): 166. DOI: 10.1186/1477-7819-11-166. ［17］ Akay CL, MericBernstam F, Hunt KK, et al. Evaluation of the MD anderson prognostic index for localregional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy［J］. Ann SurgOncol, 2012, 19(3): 901-907. DOI: 10.1245/s10434-011-2006-7. ［18］ Mittendorf EA, Buchholz TA, Tucker SL, et al. Impact of chemotherapy sequencing on localregional failure risk in breast cancer patients undergoing breastconserving therapy［J］. Ann Surg, 2013, 257(2): 173-179. DOI: 10.1097/SLA.0b013e3182805c4a. ［19］ Coates AS, Winer EP, Goldhirsch A, et al. Editor′s choice: tailoring therapiesimproving the management of early breast cancer:St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015［J］. Ann Oncol, 2015, 26(8): 1533. ［20］ HillKayser CE, Vachani C, Hampshire MK, et al. Cosmetic outcomes and complications reported by patients having undergone breastconserving treatment［J］. Int J Radiat Oncol Biol Phys, 2012, 83(3): 839-844. DOI: 10.1016/j.ijrobp.2011.08.013. ［21］曹旭晨. 整形保乳手术——乳腺外科个体化治疗的新方向［J］. 中国普外基础与临床杂志, 2013 (8): 838841. DOI: 10.7507/10079424.20130215. ［22］ Early Breast Cancer Trialists′ Collaborative Group (EBCTCG), Darby S, McGale P, et al. Effect of radiotherapy after breastconserving surgery on 10year recurrence and 15year breast cancer death:metaanalysis of individual patient data for 10 801 women in 17 randomised trials［J］. Lancet, 2011, 378(9804): 1707-1716. DOI: 10.1016/S0140-6736(11)61629-2. ［23］ Thill M. MarginProbe: intraoperative margin assessment during breast conserving surgery by using radiofrequency spectroscopy［J］. Expert Rev Med Devices, 2013, 10(3): 301-315. DOI: 10.1586/erd.13.5.

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[3]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[4]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[5]	顾花艳, 朱腾, 郭贵龙. 乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[6]	王景, 许文婷. 中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[7]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[8]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰. miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[9]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[10]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[11]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[12]	周婷, 徐少华, 梅林. 贝伐珠单抗联合卡培他滨治疗晚期乳腺癌的有效性及安全性[J]. 国际肿瘤学杂志, 2023, 50(3): 144-149.
[13]	黎立喜, 张娣, 罗扬, 马飞. PARP抑制剂在乳腺癌中的临床应用[J]. 国际肿瘤学杂志, 2023, 50(2): 91-96.
[14]	陈群响, 张晓钰, 张妍, 张凯翔, 李捷, 陈曦. 伊尼妥单抗联合长春瑞滨治疗HER2阳性转移性乳腺癌1例[J]. 国际肿瘤学杂志, 2023, 50(12): 763-765.
[15]	耿睿, 马俊强, 郭强, 牛钊峰. 老年乳腺癌患者的综合治疗方式选择倾向及其影响因素[J]. 国际肿瘤学杂志, 2023, 50(11): 650-654.